Filing Details
- Accession Number:
- 0001193125-19-302499
- Form Type:
- 13D Filing
- Publication Date:
- 2019-11-27 16:06:07
- Filed By:
- Merck Global Health Innovation Fund, Llc
- Company:
- Opgen Inc (NASDAQ:OPGN)
- Filing Date:
- 2019-11-27
- SEC Url:
- 13D Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Merck Global Health Innovation Fund | 24,597 | 0 | 24,597 | 0 | 24,597 | 0.44% |
| Merck Sharp Dohme Corp | 24,597 | 0 | 24,597 | 0 | 24,597 | 0.44% |
| Merck Co., Inc | 24,597 | 0 | 24,597 | 0 | 24,597 | 0.44% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)
OPGEN, INC.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
68373L307
(CUSIP Number)
William Taranto, President
Merck Global Health Innovation Fund, LLC
One Merck Drive
Whitehouse Station, NJ 08889
908-423-6551
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
October 28, 2019
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 68373L307 |
| 1. | Names of Reporting Persons.
Merck Global Health Innovation Fund, LLC | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
OO | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
Delaware | |||||
| Number of shares beneficially owned by each reporting person with
| 7. | Sole Voting Power
24,597* | ||||
| 8. | Shared Voting Power
0 | |||||
| 9. | Sole Dispositive Power
24,597* | |||||
| 10. | Shared Dispositive Power
0 | |||||
| 11. | Aggregate amount beneficially owned by each reporting person
24,597* | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
0.44%** | |||||
| 14. | Type of Reporting Person (See Instructions)
OO | |||||
| * | Includes (i) 2,958 shares owned previously owned; (ii) 2,400 shares of common stock and warrants to acquire 1,800 shares of common stock acquired at the First Closing pursuant to that certain Amended and Restated Securities Purchase Agreement (the A&R Purchase Agreement) which occurred on May 19, 2016; (iii) 5,469 shares of common stock and warrants to acquire 4,102 shares of common stock acquired at a Second Closing which occurred on June 27, 2016; (iv) a warrant to acquire 656 shares of common stock acquired in connection with amendment and restatement of a senior secured promissory note; and (v) 7,212 shares of common stock issued which represents payment for interest accrued on the Second Amended & Restated Senior Promissory Note through July 14, 2018. Share amounts reflect the Companys one for twenty reverse stock split on August 28, 2019. |
| ** | Such percentage was calculated based upon an aggregate of 5,588,826 Issuer shares of common stock outstanding, consisting of (i) 5,582,268 Issuer shares of common stock outstanding as of November 14, 2019, as represented by the Companys Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2019; and (ii) 6,558 shares of common stock able to be acquired by the Reporting Person upon exercise of warrants. |
| CUSIP No. 68373L307 |
| 1. | Names of Reporting Persons.
Merck Sharp & Dohme Corp. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
WC | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
New Jersey | |||||
| Number of shares beneficially owned by each reporting person with
| 7. | Sole Voting Power
24,597* | ||||
| 8. | Shared Voting Power
0 | |||||
| 9. | Sole Dispositive Power
24,597* | |||||
| 10. | Shared Dispositive Power
0 | |||||
| 11. | Aggregate amount beneficially owned by each reporting person
24,597* | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
0.44%** | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
| CUSIP No. 68373L307 |
| 1. | Names of Reporting Persons.
Merck & Co., Inc. | |||||
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
| 3. | SEC Use Only
| |||||
| 4. | Source of Funds (See Instructions)
OO | |||||
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐ | |||||
| 6. | Citizenship or Place of Organization
New Jersey | |||||
| Number of shares beneficially owned by each reporting person with
| 7. | Sole Voting Power
24,597* | ||||
| 8. | Shared Voting Power
0 | |||||
| 9. | Sole Dispositive Power
24,597* | |||||
| 10. | Shared Dispositive Power
0 | |||||
| 11. | Aggregate amount beneficially owned by each reporting person
24,597* | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐ | |||||
| 13. | Percent of Class Represented by Amount in Row (11)
0.44%** | |||||
| 14. | Type of Reporting Person (See Instructions)
CO | |||||
Introductory Note
This Amendment No. 6 (Amendment No. 6) amends the statement on Schedule 13D originally filed on July 23, 2015, and amended by prior amendments 1-5 (the Schedule 13D).
This Amendment No. 6 is being filed to report a decrease in the Reporting Persons beneficial ownership in the Company due to an increase in the Companys issued and outstanding shares resulting primarily from the Companys consummation of public offerings (i) on March 29, 2019 of 450,000 share of common stock and (ii) on October 28, 2019 of (a) 2,590,170 units (Units), with each Unit being comprised of one share of the Companys common stock, par value $0.01 per share, and one common warrant to purchase one share of common stock (the Warrants) and (b) 2,109,830 pre-funded units (Pre-Funded Units), with each Pre-Funded Unit being comprised of one pre-funded warrant (collectively, the Pre-Funded Warrants) to purchase one share of common stock and one Warrant.
On August 28, 2019, the Company effected a reverse split of their authorized and outstanding common stock at a ratio of one for twenty. All historical share amounts reflected in this report have been adjusted to reflect the reverse stock split.
Amendment No. 6 represents the final amendment to Schedule 13D and constitutes an exit filing for the Reporting Persons.
Item 1. Security and Issuer.
This statement on Schedule 13D relates to the shares of common stock, $0.01 par value per share (the Common Stock), of OpGen, Inc., a Delaware corporation (the Issuer or Company). The Companys principal executive offices are located at 708 Quince Orchard Road, Suite 160, Gaithersburg, MD 20878.
Item 2. Identity and Background.
This Schedule 13D is being filed by Merck Global Health Innovation Fund, LLC (MGHIF), Merck Sharp & Dohme Corp. (MSD) and Merck & Co., Inc. (Merck and, together with MGHIF and MSD, the Reporting Persons).
Attached as Schedule A hereto is certain information concerning the executive officers and directors of MGHIF, MSD and Merck.
Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, which it markets directly and through its joint ventures. MSD is a wholly owned subsidiary of Merck, and is also a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. MGHIF is a wholly owned subsidiary of MSD and is principally engaged in the business of investing in healthcare companies outside of its parents core operations.
MGHIF is a Delaware limited liability company. MSD is a New Jersey corporation. Merck is a New Jersey corporation.
The address of the principal executive offices of the MGHIF is One Merck Drive, Whitehouse Station, NJ 08889. The address of the principal offices of MSD is One Merck Drive, Whitehouse Station, NJ 08889. The address of the principal offices of Merck is 2000 Galloping Hill Road, Kenilworth NJ 07033.
During the last five years, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any of the persons listed on Schedule A, has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or was a party to a civil proceeding of any judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding of any violation with respect to such laws.
Item 5. Interest in Securities of the Issuer.
Item 5 is amended and restated in its entirety as follows:
(a) The Reporting Persons may be deemed to beneficially own 24,597 shares of Common Stock of which 6,558 of the 24,597 shares of Common Stock represent shares that MGHIF has the right to acquire from the Issuer pursuant to Warrants. The Common Stock voting rights represent 0.44% of the total number of shares of common stock treated as outstanding for purposes of such vote. The ownership percentages set forth in this Schedule 13D is based on information provided by the Issuer. As a result of their direct and indirect ownership of MGHIF, each of MSD and Merck may be deemed to share the Common Stock voting rights held in the name of the MGHIF.
(b) Each of the Reporting Persons has the power to vote or direct the vote of the 18,039 votes that may be cast in actions taken by common stockholders as a result of the shares of Common Stock held in the name of the MGHIF. Each of the Reporting Persons has sole or shared power to direct the disposition of any shares of Common Stock.
(c) To the best knowledge of the Reporting Persons, none of the Reporting Persons nor the individuals named in Schedule A to this Schedule 13D has effected a transaction in shares of the Issuer during the past 60 days.
(d) Other than the Reporting Persons, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Reporting Persons securities.
(e) The Reporting Persons have ceased to be the beneficial owners of more than five percent of the Companys Common Stock based on the number of shares of Common Stock outstanding as reported by the Company as of November 14, 2019.
Signatures
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Dated this 27th day of November, 2019.
| MERCK GLOBAL HEALTH INNOVATION FUND, LLC | ||
| By: | /s/ Jon Filderman | |
| Name: Title: | Jon Filderman Secretary | |
| MERCK SHARP & DOHME CORP. | ||
| By: | /s/ Faye C. Brown | |
| Name: Title: | Faye C. Brown Assistant Secretary | |
| MERCK & CO., INC. | ||
| By: | /s/ Faye C. Brown | |
| Name: Title: | Faye C. Brown Senior Assistant Secretary | |
SCHEDULE A
The name, present principal occupation or employment, and the name, principal business and address of any corporation or other organization in which such employment is conducted, of each of the executive officers and directors of each of the Reporting Persons is set forth below.
MERCK GLOBAL HEALTH INNOVATION FUND, LLC
EXECUTIVE OFFICERS AND DIRECTORS
| Name | Principal Occupation | Business Address | Citizenship | |||
| Donna Daidone-Yahara | Assistant Vice President, Finance | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Robert Davis | Manager / Vice President | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Katie Fedosz | Assistant Secretary | 2000 Galloping Hill Road Kenilworth NJ, 07033 | USA | |||
| Jon Filderman | Manager/ Secretary | 2000 Galloping Hill Road Kenilworth NJ, 07033 | USA | |||
| Julie Gerberding | Manager | 2000 Galloping Hill Road Kenilworth NJ, 07033 | USA | |||
| Aaron Rosenberg | Manager | 2000 Galloping Hill Road Kenilworth NJ, 07033 | USA | |||
| Timothy Dillane | Assistant Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Juanita Lee | Assistant Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Salvatore Lombardo | Vice President, Tax | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Caroline Litchfield | Senior Vice President and Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Faye C. Brown | Assistant Secretary | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Joseph Miletich | Manager | 126 E. Lincoln Avenue Rahway, NJ 07065 | USA | |||
| Joseph Promo | Assistant Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Frank Clyburn | Manager | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Michael G. Schwartz | Assistant Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| William J. Taranto | Manager / President | One Merck Drive, Whitehouse Station, NJ 08889 | USA | |||
| Susan Shiff | Manager | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Jim Scholefield | Manager | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Jan Van Acker | Manager | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
MERCK SHARP & DOHME CORP.
EXECUTIVE OFFICERS AND DIRECTORS
| Name | Principal Occupation | Business Address | Citizenship | |||
| Timothy Dillane | Assistant Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Katie Fedosz | Assistant Secretary | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Jon Filderman | Director / Vice President | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Rita Karachun | Director / President | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Juanita Lee | Assistant Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Salvatore Lombardo | Assistant Secretary, Tax | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Caroline Litchfield | Director / Senior Vice President and Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Jerome Mychalowych | Vice President, Tax | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Faye C. Brown | Assistant Secretary | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Geralyn Ritter | Secretary | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Michael G. Schwartz | Assistant Treasurer | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
MERCK & CO., INC.
EXECUTIVE OFFICERS
| Name | Principal Occupation | Business Address | Citizenship | |||
| Kenneth C. Frazier | Chairman, President and Chief Executive Officer / Director, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Sanat Chattopadhyay | Executive Vice President and President, Merck Manufacturing Division (MMD), Merck & Co., Inc. | One Merck Drive, Whitehouse Station, NJ 08889-0100 | USA | |||
| Robert Davis | Executive Vice President, Chief Financial Officer and Global Services, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Richard R. DeLuca, Jr. | Executive Vice President and President, Merck Animal Health | Giralda Farms 2 Madison, NJ 07940 | USA | |||
| Julie Gerberding | Executive Vice President and Chief Patient Officer, for Strategic Communications, Global Public Policy and Population Health, Merck & Co., Inc. | 351 N. Sumneytown Pike North Wales, PA 19454 | USA | |||
| Steven C. Mizell | Executive Vice President, Chief Human Resources Officer, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Roger Perlmutter | Executive Vice President and President, Merck Research Laboratories | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Frank Clyburn | Executive Vice President, Chief Commercial Officer, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Jim Scholefield | Executive Vice President, Chief Information and Digital Officer, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Michael Nally | Executive Vice President, Chief Marketing Officer, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Jennifer Zachary | Executive Vice President and General Counsel, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
MERCK & CO., INC.
DIRECTORS
| Kenneth C. Frazier | Chairman, President and Chief Executive Officer, Merck & Co., Inc. | 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Leslie A. Brun | Chairman and Chief Executive Officer, Sarr Group, LLC | 435 Devon Park Drive, 700 Building, Wayne, PA 19087 | USA | |||
| Thomas R. Cech | Investigator, Howard Hughes Medical Institute and Faculty, University of Colorado. | University of Colorado, University of Colorado at Boulder 3415 Colorado Avenue, JSCBB Boulder, CO 80309-0215 | USA | |||
| Mary Ellen Coe | President, Google Customer Solutions, Google | Alphabet Inc. 1600 Amphitheatre Parkway Mountain View, CA 94043 | USA | |||
| Thomas H. Glocer | Retired Chief Executive Officer, Thomson Reuters Corporation | 6 East 43rd Street, 25th Floor New York, NY 10022 | USA | |||
| Pamela J. Craig | Former Chief Financial Officer, Accenture, plc | c/o Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Rochelle B. Lazarus | Chairman Emeritus, Ogilvy & Mather | 636 11th Avenue, New York, NY 10036-2010 | USA | |||
| Paul B. Rothman, M.D. | Dean of Medical Faculty and Vice President for Medicine, The Johns Hopkins University, and CEO John Hopkins Medicine | 733 N. Broadway, Suite 100 Baltimore, MD 21205-2196 | USA | |||
| Patricia F. Russo | Chairman, Hewlett Packard Enterprise Company | Hewlett Packard Enterprise 300 Hanover Street Mailstop 1050 Palo Alto, CA 94304 | USA | |||
| Inge G. Thulin | Former Executive Chairman, President and Chief Executive Officer, 3M Company | c/o Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, NJ 07033 | USA | |||
| Wendell P. Weeks | President, Chairman and Chief Executive Officer, Corning Incorporated | 1 Riverfront Plaza, Corning, NY 14831-0001 | USA | |||
| Peter C. Wendell | Managing Director, Sierra Ventures | 1400 Fashion Island Blvd. Suite 1010 San Mateo, CA 94404 | USA | |||